Drugs / GR2102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06313697 | Mar 2024 → Jan 2025 | respiratory syncytial virus infectious disease | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GR2102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06313697 ↗ |